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INTRODUCTION
Psoriasis is a chronic recurrent inflammatory skin 
disease affecting 2-3% of the world’s population (1). 
This condition is a systemic immunological disease 
that is mainly driven by activated T-helper 1 (Th1) 
and Th17 lymphocytes. Atherosclerosis is also char-
acterized by Th1-related inflammation, both systemi-
cally and locally in arterial walls and atherosclerotic 
plaques (2). It appears that the inflammatory mecha-
nisms resulting in psoriasis and atherosclerosis over-
lap significantly.
When assessing coronary artery disease and gen-
eralized atherosclerosis, carotid artery intima-media 
thickness (CIMT) detected by high-resolution B-mode 
ultrasound is a good indicator of an increased risk of sub-
clinical atherosclerosis (3-7). CIMT is determined by the 
distances between the vascular intima and media com-
posed of endothelium, smooth muscle, and connective 
tissue (7). The area between the endothelial and smooth 
muscle layers is also the area of lipid deposition and 
plaque formation in patients with atherosclerosis (8). 
Acta Dermatovenerol Croat     2015;23(3):171-177            CLINICAL ARTICLE
ABSTRACT Previous studies have associated severe psoriasis and psoriat-
ic arthritis with an increased risk of atherosclerosis. However, the associa-
tion between patients with mild-to-moderate plaque-type psoriasis and 
atherosclerosis has yet to be studied in depth. This study investigates a) 
possible correlations between carotid intima-media thickness (CIMT) and 
serum fetuin-A levels in patients with mild-to-moderate psoriasis and b) 
correlations between psoriasis severity index (PASI) and fetuin-A levels. 
The latter correlation was recently reported to be important for wound 
healing and vascular calcification. In this prospective study, a total of 
70 patients with mild-to-moderate psoriasis and 66 control participants 
were included. PASI, CIMT, and serum fetuin-A levels were examined in all 
patients. Although the difference in fetuin-A values was not statistically 
significant between patients with mild-to-moderate plaque-type psoria-
sis and control groups (P=0.401), the CIMT levels in the psoriasis group 
were significantly higher than the control group (P=0.002). There were no 
correlations among fetuin-A levels, CIMT, and PASI. This study establishes 
an association between mild to moderate psoriasis and atherosclerosis. 
This study also concludes that, similarly to patients with severe psoriasis, 
CIMT levels are a better indicator of cardiovascular risk than serum fe-
tuin-A levels in patients diagnosed with mild-to-moderate plaque-type 
psoriasis. 
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Fetuin-A is a serum glycoprotein that is synthe-
sized mainly by hepatocytes. A consensus has not 
been reached regarding how fetuin-A affects the 
cardiovascular system, including any possible con-
tributions to atherosclerosis. Mori et al. hypothesize 
that fetuin-A contributes to vascular disease in two 
distinct ways: by increasing insulin resistance and 
dyslipidemia and by reducing ectopic calcification 
(9). These authors also report that varied results were 
obtained from different patients depending on the 
severity of disease (9). To our knowledge, there is only 
one report on the status of fetuin-A in patients with 
psoriasis (10).  
Furthermore, there are reports on fetuin-A inter-
acting with transforming growth factor (TGF)-β and 
epidermal growth factor (EGF), which play an impor-
tant role in the pathogenesis of psoriasis (9). In this 
study we explored a) possible associations between 
fetuin-A and the severity of psoriasis skin lesions and 
b) correlations between fetuin-A and subclinical ath-




This was a prospective cross-sectional case-con-
trolled study of 70 patients who attended our derma-
tology clinic and who were diagnosed with mild-to-
moderate plaque-type psoriasis between April 2012 
and March 2014. A control group of 66 healthy volun-
teers, matched for age, gender, and body mass index 
were recruited. 
Age, sex, body mass index, blood pressure, and 
CIMT were measured and recorded for all of the pa-
tients and volunteers. Psoriasis area and severity in-
dex (PASI) was calculated in patients with psoriasis. 
The following parameters were assessed in all patients 
and healthy volunteers at the time of clinical evalua-
tion: complete blood count, erythrocyte sedimenta-
tion rate (ESR), C-reactive protein (CRP), rheumatoid 
factor (Rf ), serum urea, creatinine, uric acid, aspartate 
aminotransferase (AST), alanine aminotransferase 
(ALT), serum glucose, total cholesterol, high-density 
lipoprotein (HDL), low-density lipoprotein (LDL), and 
triglycerides (after an overnight fast).
Patients with any of the following criteria that 
could affect their cardiovascular status were exclud-
ed from the study: history of smoking; hypertension 
(systolic blood pressure >140 mm Hg and/or diastolic 
blood pressure >90 mm Hg); body mass index >30 
kg/m2, coronary artery disease, dyslipidemia (total 
cholesterol and triglyceride levels in fasting plasma 
>200 mg/dL), diabetes mellitus (fasting glucose lev-
els >110 mg/dL), chronic renal failure, thyroid dis-
ease, rheumatic disease, previous systemic treatment 
of cardiovascular disease, pregnancy, and a PASI ≥12 
(12).
The study was approved by the Ethics Committee 
of the University of Sifa and was conducted accord-
ing to the ethical principles of the Declaration of Hel-
sinki. All patients provided informed consent before 
participating. 
Psoriasis areas and severity index score
The psoriasis areas and severity index (PASI) score 
was utilized as an objective method to score psoriasis 
severity, induration, erythema, and scaling on body 
surfaces of each patient (13). The PASI score was cal-
culated in all patients as described by Fredriksson 
and Pettersson (14). A PASI score below 7 was defined 
as mild, between 7 and 12 as moderate, and above 12 
as severe disease (12).
Carotid intima-media thicknesses
The intima-media thicknesses (IMT) of the com-
mon carotid artery (CCA) was obtained using a real-
time ultrasound scanner (Siemens, Acuson Antares, 
Germany) with a 7.5 MHz, 50 mm linear transducer. 
CIMT measurements were obtained while the patient 
was lying in the supine position with their neck rotat-
ed in the opposite direction of the examining physi-
cian. CCA images were obtained to measure IMT using 
three different-angled views for each vessel. Initially, 
a transverse scan of the CCA was performed on the 
longest extension possible, from the base of the neck 
to the carotid bulb. At least three IMT points were 
measured in the near and far walls of the most thick-
ened area of each vessel. Lateral wall measurements 
were also taken when both thickening was evident 
and accurate images were possible. Subsequently, 
two longitudinal view scans of the vessel were taken 
in the posterolateral (PL) position, with the transducer 
positioned parallel to the posterior border of the ster-
nocleidomastoid muscle, and in the anterolateral (AL) 
position, with the transducer positioned parallel to 
the anterior border of the sternocleidomastoid mus-
cle. At least three IMT measurements were obtained 
for each near and far wall of each position. Optimal B-
mode settings of gain, depth, focal zone placement, 
and compression were individually adjusted for each 
vessel to enhance the arterial wall structures and im-
age quality. IMT was measured manually using elec-
tronic calipers, as previously described by Sidhu and 
Desai (15). The maximum IMT value was selected for 
each angle. For further data analyses, the maximum 
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value of either the right or left carotid artery was also 
measured. An IMT of greater than 1.0 mm was consid-
ered to be abnormal (16).
Biochemical parameters
For sample preparation, 8 mL of venous blood 
was collected in serum tubes (Vacuette-Z Serum Sep 
Clot Activator, Greiner bio-one GmbH, Kremsmün-
ster, Austria) and centrifuged at 2000 g after clotting 
for 10 min at room temperature. Serum samples were 
stored at -80°C until time of the assay. Fetuin-A was 
measured with a human enzyme-linked immunosor-
bent assay (ELISA) kit (analytical sensitivity: 0.37 ng/
mL) (Alfha-2-Heremans Schid Glycoprotein, Uscn Life 
Science Inc. Wuhan, China).
Statistical analyses
The normality of data was analyzed using the Kol-
mogorov-Smirnov Test. All numerical variables with a 
normal distribution were expressed as a mean ± stan-
dard deviation, while data that were not determined 
to be normally distributed were expressed as median 
with interquartile ranges (IR). Continuous variables 
were compared using Student’s t-test or the Mann-
Whitney U test. Correlations among CIMT, PASI, and 
fetuin-A were determined using Pearson’s partial cor-
relation calculation. P values of less than 0.05 were 
considered statistically significant. Statistical analyses 
were performed using the Statistical Package for the 
Social Sciences (SPSS) version 20 (SPSS, Chicago, IL).
RESULTS
The demographics of patients and controls, in-
cluding age, sex, and body mass index, were similar. 
Total cholesterol, LDL, HDL, triglyceride, ESR, CRP, se-
rum glucose, AST, urea, creatinine, and uric acid lev-
els were not statistically significant between psoriasis 
and control groups. Rf and ALT levels were found to 
be significantly higher in the psoriasis group (P=0.021, 
P=0.018, respectively). 
Median CIMT levels were significantly higher in 
patients with mild-to-moderate psoriasis compared 
to controls (patients with psoriasis: 0.80 (0.36), con-
trols: 0.55 (0.24); P=0.002) (Figure 1). The difference in 
mean serum concentration of fetuin-A was not sta-
tistically significantly between groups (patients with 
psoriasis: 4.599±3.429 ng/mL, controls: 3.677±2.616 
ng/mL; P=0.401) (Figure 2). Demographic informa-
tion, laboratory findings, CIMT levels, and PASI scores 
of patients with psoriasis and controls are presented 
in Table 1. There were no correlations found among 
the serum fetuin-A levels, CIMT levels, and PASI scores. 
Correlations of fetuin-A with CIMT, PASI, glucose, and 
LDL for all patients and controls are presented in Ta-
ble 2.
DISCUSSION
Although psoriasis was previously described as a 
disease that affects only the skin and joints, many re-
cent publications have described it as a systemic dis-
ease that is characterized by chronic inflammation. 
Autoimmune chronic inflammatory conditions, such 
as rheumatoid arthritis, systemic lupus erythemato-
sus (SLE), and psoriasis, are associated with increased 
cardiovascular risk (17). In previous studies, severe 
psoriasis or psoriatic arthritis have been reported to 
be associated with an increased risk of atheroscle-
rosis (18,19). However, the association between pa-
Figure 2. Box-plot graphics of fetuin-A levels in pa-
tients with psoriasis and controls.
Figure 1. Box-plot graphics of carotid intima-media 
thickness (CIMT) levels in patients with psoriasis and 
controls.
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tients with mild-to-moderate plaque-type psoriasis 
and atherosclerosis had not been fully investigated.
In this study, CIMT levels were found to be 
significantly higher in patients with mild-to-moder-
ate psoriasis compared to controls (patients with 
psoriasis: 0.80 (0.36), controls: 0.55 (0.24); P=0.002). 
However, we did not find any correlation between 
CIMT and PASI scores. These results seem to support 
previous reports that there is no correlation between 
disease activity and CIMT scores (18,20).
Psoriasis is characterized by excessive growth 
and aberrant differentiation of keratinocytes in skin 
lesions. Flisiak et al. previously reported that some 
inflammatory cytokines, including transforming 
growth factor (TGF) β1, are involved in the patho-
genesis of psoriasis (21,22). Fetuin-A acts as an anti-
inflammatory mediator and natural antagonist of 
TGF-β (9). In addition, TGF-β is important for negative 
regulation of keratinocyte proliferation. We hypoth-
esized that reduced TGF-β in patients with psoriasis 
may be associated with increased levels of fetuin-A, 
and that fetuin-A is higher in patients with psoriasis 
when compared to healthy volunteers, which may be 
related to the observed PASI and/or correlation with 
CIMT.
Epidermal growth factor (EGF) appears to play a 
crucial role in the pathogenesis of psoriasis (23). 
Wang et al. demonstrated that fetuin-A promotes 
HaCaT migration via signaling pathways that are simi-
lar to the pro-migratory pathways provoked by epi-
dermal growth factor (EGF) and transforming growth 
factor-α stimulation (11). They demonstrated that a 
blockade of EGF receptor signaling has a limited ef-
fect on fetuin-A-promoted “wound closure” in prima-
ry human keratinocytes but significantly inhibits the 
effect of fetuin-A on HaCaT cells. 
In this study, we aimed to investigate the possible 
associations between a) fetuin-A levels and the sever-
ity of plaque-type psoriasis and b) fetuin-A levels and 
atherosclerosis. However, no correlations between 
fetuin-A and PASI scores were observed.
Our analysis expands upon a study by Gerdes et 
al., in which it is hypothesized that the inflammatory 
status of patients with psoriasis resulted in a de-
crease in systemic fetuin-A levels. This decrease in 
fetuin-A may result in an increased risk of vascular 
calcification and could provide an explanation for 
how systemic inflammation during psoriasis contrib-
utes to the observed cardiovascular comorbidity (10). 
Table 1. Demographics, laboratory findings, carotid intima-media thickness (CIMT) levels, and psoriasis  
severity index (PASI) scores of 70 patients with mild-to-moderate psoriasis and 66 matched controls*
Variable Patients (n=70)
Mean ± SD or median (IR)
Controls (n = 66)
Mean ± SD or median (IR)
P
Age, years 34.03±10.29 32.33±9.25 0.617
Men/women 36/34 33/33 0.934
Body mass index, kg/m2 25.45±4.53 25.94±4.89 0.753
Serum creatinine, mg/dL 0.81±0.30 0.65±0.10 0.077
Serum urea, mg/dL 27.57±10.36 23.41±5.053 0.191
Urıc acid, mg/dL 4.72±1.26 3.91±1.02 0.051
CRP level, mg/dL 0.15 (0.24) 0.13 (0.20) 0.874
ESR, mm/hour 7.00 (9.00) 10.50 (13.00) 0.309
RF, IU/dL 9.00 (2.00) 8.00 (0.68) 0.210
AST, U/L 18.97±4.34 17.00±2.89 0.087
ALT,  U/L 22.74±11.67 15.9167±6.59 0.018
Total cholesterol, mg/dL 176.48±38.09 183.66±26.87 0.550
HDL cholesterol, mg/dL 51.97±16.15 55.03±13.17 0.557
LDL cholesterol, mg/dL 110.24±33.19 107.81±37.66 0.840
Triglycerides, mg/dL 128.57±102.33 112.91±75.65 0.579
Fasting serum glucose, mg/dL 91.00 (15.00) 90.50 (11.25) 0.660
Serum Fetuin A, ng/mL 4.59±3.42 3.67±2.61 0.401
CIMT, mm 0.80 (0.36) 0.55 (0.24) 0.002
PASI 8.32±5.43 - -
*Values are the mean ± standard deviation (SD) or median (interquartile range-IR). CRP: C-reactive protein; ESR: erythrocyte 
sedimentation rate; HDL: high-density lipoprotein; LDL: low-density lipoprotein; CIMT: carotid intima-media thickness; PASI: 
psoriasis areas and severity index; RF: rheumatoid factor; AST: aspartate aminotransferase; ALT: alanine aminotransferase.
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Gerdes et al. found low levels of fetuin-A in patients 
with chronic kidney disease, dialysis patients, and 
patients with end-stage renal disease with evidence 
of inflammation (24,25). In hemodialysis patients, low 
levels of fetuin-A were associated with increased car-
diovascular and all-cause mortality (26). These find-
ings are supported by the repeatedly described ob-
servation that fetuin-A is a negative acute phase pro-
tein that is down-regulated by acute inflammation. In 
the rat liver, it was shown that tumor necrosis factor 
alpha (TNF-a) can reduce fetuin-A gene expression, 
and in humans, this was shown for Interleukin (IL) 6 
and IL-1b (27). Gerdes et al. found a significant reduc-
tion fetuin-A in patients with psoriasis with and with-
out psoriatic arthritis (10). 
In our study, the mean serum concentration of fe-
tuin-A was found to be higher in patients with psoria-
sis (4.59±3.42) as compared with controls (3.67±2.61), 
however, this difference was not statistically signifi-
cant (P=0.401).
Ix et al. reported that among 1,375 community-liv-
ing individuals without prevalent clinical cardiovas-
cular disease, lower fetuin-A levels are independently 
associated with greater coronary artery calcification 
severity but not peripheral arterial disease or CIMT. 
They report that fetuin-A might initiate calcium depo-
sition with in the vasculature but not atherosclerosis 
directly. Low fetuin-A levels also may cause patients 
to be predisposed to greater calcium deposition but 
not necessarily the initiation or progression of athero-
sclerosis (28). Our study and several others support 
this hypothesis (29,30). In our study, serum fetuin-A 
levels of patients with psoriasis were not significantly 
reduced as compared with controls. This could be be-
cause the CIMT levels of patients were found to be 
higher than that of controls. We also found that mild-
to-moderate plaque-type psoriasis patients did not 
exhibit as much calcification as patients with severe 
psoriasis. 
Fetuin A has also been reported to impair insulin 
signaling and adipocyte function. Fetuin A is associ-
ated with insulin resistance, diabetes mellitus, and 
obesity, all of which have been previously associated 
with psoriasis (9). 
In this study, we observed a correlation between 
serum fetuin-A levels and fasting glucose, as well as 
between fetuin-A and LDL cholesterol. 
A limitation of our study was that only a small 
number of patients were enrolled. Cross-sectional 
data from this small cohort does not allow for causal-
ity to be established. Future directions may include 
expanding our study to include more patients. An-
other limitation is that we did not analyze men and 
women separately.
CONCLUSION
Most importantly, this study describes an associa-
tion between mild-to-moderate psoriasis and athero-
sclerosis, similarly to severe psoriasis. Interestingly, 
this association was seen in patients without taking 
other cardiovascular risk factors into consideration.
We recommend that when assessing the cardio-
vascular disease risk of patients with psoriasis, physi-
cians should measure CIMT rather than the less ap-
propriate serum fetuin-A values, as many other meta-
bolic events influence fetuin-A levels. 
Future studies should evaluate the effect of fetuin-
A on excessive growth and aberrant differentiation of 
keratinocytes. In conclusion, the measurement of fe-
tuin-A levels in psoriasis plaques is more appropriate 
than the measurement of levels of serum fetuin-A.  
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